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Abstract Objective of the study To determine the extent
and nature of unlicensed/off-label prescribing patterns in
hospitalised children in Palestine. Setting Four paediatric
wards in two public health system hospitals in Palestine
[Caritas children’s hospital (Medical and neonatal inten-
sive care units) and Rafidia general hospital (Medical and
surgical units)]. Method A prospective survey of drugs
administered to infants and children \18 years old was
carried out over a five-week period in the four paediatric
wards. Main outcome measure Drug-licensing status of all
prescriptions was determined according to the Palestinian
Registered Product List and the Physician’s Desk Refer-
ence. Results Overall, 917 drug prescriptions were
administered to 387children. Of all drug prescriptions, 528
(57.5%) were licensed for use in children; 65 (7.1%) were
unlicensed; and 324 (35.3%) were used off-label. Of all
children, 49.6% received off-label prescriptions, 10.1%
received unlicensed medications and 8.2% received both.
Seventy-two percent of off-label drugs and 66% of
unlicensed drugs were prescribed for children \2 years.
Multivariate analysis showed that patients who were
admitted to the neonatal intensive care unit and infants
aged 0–1 years were most likely to receive a greater
number of off-label or unlicensed medications (OR 1.80;
95% CI 1.03–3.59 and OR 1.99; 95% CI 0.88–3.73,
respectively). Conclusion The present findings confirmed
the elevated prevalence of unlicensed and off-label paedi-
atric drugs use in Palestine and strongly support the need to
perform well designed clinical studies in children.
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Impact statements
• Infants aged less than one year old were the most likely
group to receive a greater number of off-label or unli-
censed medications compared to older children.
• In Palestine, off-label drug use occurs considerably
more frequently than unlicensed use in hospitalised
children.
• The overall level of unlicensed and off-label paediatric
prescribing suggests the need to perform well designed
clinical studies in children so that dosing schedules in
the future can be evidence based.
Introduction
Infants and children represent a large proportion of the
population in developing countries. As in all countries,
infants and young children are especially vulnerable to
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illnesses and the harmful effects of medicines. Although
there has been important progress in paediatric clinical
pharmacology, there is still a lack of information regarding
many relevant aspects of therapeutics in childhood, par-
ticularly concerning pharmacokinetics, pharmacodynamics
and pharmacoepidemiology [1].
Growing children have a constantly changing physiol-
ogy and it is therefore important that doses are adjusted
in a manner that ensures both safety and effectiveness.
Although some medications used in children have been
subjected to clinical trials and have been specifically
licensed for use in this age group, many medicines have not
been appropriately tested in children or are not available in
a formulation that is suitable for children and as such are
used outside the terms of their license, i.e. off-label or
unlicensed [2–5]. The main reason for off-label medicine
use among children is that the medicine is prescribed
outside the licensed dosage range, for an age group for
which the drug is not licensed, for a different indication or
by a different route of administration [6]. Unlicensed
medicines are also commonly used. This normally involves
drugs which are not available in a formulation suitable for
administration to young children e.g. tablets crushed and
reformulated as a suspension. There is a concern because
adverse drug reactions in children may be more common
during unlicensed and off-label treatment, and the practice
may result in either over- or underdosing of medicines in
different age groups [7–10].
The extent of prescribing of medicines for off-label and
unlicensed use has been quantified in studies from North
and South America, Australia, and Europe [11, 12]. These
studies show that the situation varies across countries
because of national differences in licensing status of
medicinal products and in clinical practice. In a recent
review of 24 studies from 12 different countries (mostly
European), the proportion of hospitalised children who
received at least one prescription for off-label use or
unlicensed medicine ranged from 36 to 100% [12]. The
practice is also common in primary care [8]. The pre-
scribing of unlicensed and off-label medications is not
governed by legislation and remains the responsibility of
the prescribing clinician [9].
Aim of the study
The aim of the present study was to obtain information on
the prescribing patterns of medicines to hospitalised chil-
dren in public health system hospitals in Palestine. More
specifically, the goal was to determine the extent of use of
medicines which do not have a marketing authorisation e.g.
tablets crushed and made into a suspension or a chemical
used as a medicine (unlicensed) and of medicines used
outside the terms of their product license (off-label) with
respect to age/weight, dose/frequency, dosage form and
route of administration and to explore factors associated
with receiving off-label or unlicensed medicines among
hospitalised children.
Methods
This study was approved by the Committee for Clinical
Research, Hospital Administration Department, Ministry of
Health, Palestine. The research was performed in the
medical and neonatal intensive care wards at the Caritas
Children’s Hospital and the paediatric medical and surgical
wards at the Rafidia Hospital over a 5 week period during
March and April 2010. The wards in Rafidia hospital in
Nablus City, North Palestine had a mixture of general
paediatric, gastrointestinal and respiratory cases. The
wards in Caritas Children’s Hospital in Bethlehem, South
Palestine cater for children with a variety of acute illnesses
(e.g. pneumonia, soft tissue and skeletal infections) and
sub-acute or chronic conditions (e.g. failure to thrive,
abdominal pain and anaemia). Data on all patients admitted
to these wards over the 5 week study period were collected.
Data collected included the date of birth, diagnosis, med-
ication prescribed, and dose and route of administration.
The following items were not included in the study: stan-
dard intravenous replacement solutions, flushes for intra-
venous lines, blood products, topical anaesthetic creams
and medications used in clinical trials. The study included
children \18 years of age who were hospitalised for at
least 24 h.
Each medicine recorded was reviewed for unlicensed or
off-label use status, based on the information in their
respective product licenses in Palestine. The follow-
ing were considered unlicensed: modified formulations
including extemporaneous preparations, formulations pre-
pared under a ‘specials’ manufacturing license, imported
drugs (which are not part of the Palestinian Registered
Product List, PRPL) and chemicals used as drugs [4, 6, 13].
The off-label category included all medicines where the
prescription showed a discrepancy with the license label-
ling information for age (or weight), dose (or frequency) or
route of administration. Some medicines were classified
off-label for more than one reason. As primary reference
sources, the Palestinian Registered Product List [14] and
the Physician’s Desk Reference [15] were used. The latter
reference is used in Palestine as a source of information for
the licensing status of medicines, particularly in children.
Data were analysed using SPSS (version 18 for Win-
dows; SPSS Inc, Chicago, IL, USA). The differences in
proportions between the four wards were compared using
the Pearson’s chi-squared test. Continuous variables were
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compared using the Kruskal–Wallis test. The probability of
a child receiving an unlicensed or off-label medicine and
the factors associated with such prescribing were estimated
utilising the odds ratio approach, the calculations being
performed by logistic backward stepwise regression, with
the dependent variable being the prescription of an off-
label or unlicensed medicine. A P-value of less than 0.05
was considered significant.
Results
Three hundred and eighty-seven children were involved in
the study; 182 in Caritas medical wards, 42 in the Cartias
neonatal intensive care unit, 143 in the Rafidia medical
wards and 20 in the Rafidia surgical ward. Children were
either in hospital at the start of the study or admitted over
the study period. Of these, 236 (61%) were male and 151
(39%) were female. The ages of the patients ranged from
4 days to 16 years (mean ± SD = 23.5 ± 32.7 months;
median = 12 months). The minimum and maximum
numbers of prescribed medicines per patient were 1 and 9
respectively (mean ± SD = 2.35 ± 1.44; median = 2).
In the medical wards, the most common diagnoses
according to the World Health Organisation International
Classification of Diseases (ICD) [16] were respiratory
diseases (including upper and lower respiratory tract
infections; 44%), certain infections and parasitic diseases
(apart from respiratory tract infections; 20%) and diseases
of the digestive system (16%); in the surgical ward, most of
the children had surgical procedures under general or
regional anaesthesia and in the ICU the most frequently
encountered condition was respiratory distress syndrome.
A total of 66 different medicines were administered to the
387 patients. The 5 most commonly prescribed medicines
were cefuroxime, salbutamol, paracetamol, ceftriaxone and
dexamethasone.
Of the 387 children, 199 (51.4%) were prescribed at
least one off-label or unlicensed medicine. One hundred
and ninety-two (49.6%) children received prescriptions for
off-label use, 39 (10.1%) for unlicensed medicines and 32
(8.2%) received both types of medicines.
Of all the prescriptions (n = 917), 528 (57.8%) were
licensed for use in children, 65 (7.1%) were unlicensed and
324 (35.3%) were used off-label. The breakdown of the
data by hospital and ward are presented in Table 1. Sev-
enty-two percent of off-label drugs and 66% of unlicensed
drugs were prescribed for children under 2 years old.
Antibiotics for systemic use and bronchodilators were
among the five most frequently prescribed off-label drugs
in the four paediatric study wards (Table 2). Altered dose
and use of medicine outside the age range were the most
common categories of off-label medication use. On the
other hand, the most frequent reason for unlicensed
medicine use (approximately 80%) was modification of
licensed drugs (dispensing a drug in a different form, e.g.
tablets crushed to prepare suspensions). The numbers and
types of unlicensed medication uses are summarised in
Table 3.
Predictors of receiving an off-label or unlicensed med-
ication are shown in Table 4. In multivariate analysis,
patients who were admitted to the neonatal intensive care
unit were most likely to receive an off-label or unlicensed
medicine compared with patients who were admitted to a











Medical (Caritas) 182 (46.9) 224 (61.0) 115 (31.3) 28 (7.6) 367 (40.0)
Neonatal (Caritas) 42 (10.8) 37 (37.0) 55 (55.0) 8 (8.0) 100 (10.9)
Surgical (Rafidia) 20 (5.2) 47 (68.1) 18 (26.0) 4 (5.8) 69 (7.5)
Medical (Rafidia) 143 (36.9) 220 (57.5) 136 (35.7) 25 (8.4) 381 (41.5)
Table 2 The five most frequently prescribed off-label drugs (% of all prescriptions) in each ward
Caritas Rafidia
Rank Medical (n = 115) (%) Neonatal (n = 55) (%) Medical (n = 136) (%) Surgical (n = 18) (%)
1st Salbutamol 20.0 Adrenaline 23.6 Paracetamol 18.3 Dexamethasone 22.2
2nd Cefuroxime 15.6 Cefotaxime 18.1 Cefuroxime 13.2 Ranitidine 11.1
3rd Dexamethasone 7.8 Gentamicin 16.3 Ceftriaxone 9.5 Vancomycin 11.1
4th Ipratropium 7.0 Dexamethasone 5.4 Dexamethasone 7.3 Diazepam 5.6
5th Ceftriaxone 6.0 Amikacin 3.6 Ibubrofen 5.9 Midazolam 5.6
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medical or surgical ward (OR 1.80; 95% CI 1.03–3.59). It
can be seen that infants aged 0–1 year were also at higher
risk of receiving an off-label or unlicensed medications
than other age groups (OR 1.99; 95% CI 0.88–3.73).
Discussion
To the best of our knowledge, this is the first study to
investigate the extent and nature of unlicensed and off-
label medication use in children in Palestine. Results show
a high prevalence of unlicensed and off-label drug use
there. The results indicate that off-label use occurs con-
siderably more frequently (35.3%) than unlicensed use
(7.1%). The proportions are in parallel to those found in
France [17] (62% and 10%), the Netherlands [18, 19] (62
and 14%), Italy (50.5 and 12%) [4] and in the United
Kingdom [7, 8] (54.7 and 10%; 55% combined). The
slightly lower unlicensed use can be explained by the
more widespread use of extemporaneously prepared
formulations, manufactured by hospital pharmacies, in
European countries [2].
As expected, in the present study, unlicensed and off-
label drug use was more prevalent in neonatal wards when
compared with paediatric medical or surgical wards. The
general lack of availability of licensed medicines for
newborns and infants is an important factor in this regard
[20, 21]. In a recent study by Neubert et al., only 38% of
the medicines prescribed in a neonatal intensive care unit
in Germany had information about their use in patients less
than 1 month of age in their SPC (i.e. 62% of all medi-
cations were used in an unlicensed or off-label manner in
neonates). Furthermore, 69.9% of all neonates received at
least one prescription of medications that are unlicensed or
off-label in neonates [22]. In the present study, 63% of the
prescriptions in Caritas neonatal intensive care unit were
for either unlicensed or off-label use. Similar percentages
of unlicensed/off-label prescription episodes in neonates
were also reported by Conroy et al. and O’Donnell et al.
(64.6 and 58%, respectively) [20, 23].
The most frequently prescribed medicines used in an
off-label or unlicensed manner were antibacterials and
bronchodilators. This concurred with a recent study con-
ducted in the US where inhaled bronchodialators (30.4%)
and antimicrobials (14.8%) were the most commonly pre-
scribed unlicensed/off-label medication classes in a pae-
diatric emergency department [24]. In the present study,
however, antibiotic use (44% of total medications) was
high compared to other reports from similar studies in other
countries [25–27]. This high prevalence can be partially
explained by the high incidence of bacterial infections to
the overall illness burden in Palestine [28] and by the fact
that over prescription of antibiotics is common practice in
hospitalised children in Palestine [29].
Off-label use was mainly attributable to the use of dif-
ferent doses and dosing frequencies to those recommended
in the product license, a finding consistent with other
studies [30]. In a recent review, the most frequent reason
for off-label prescribing reported in 12 studies was devia-
tion from dosage recommendations [12]. An overdose
increases the risk of adverse drug reactions, whereas an
underdose may not be therapeutically effective [12]. Such
use, however, is not always inappropriate, and in some
cases was justified, e.g. ceftriaxone and cefuroxime were
Table 3 Examples of
unlicensed medications and
their frequencies in the study
Medicines n License category
Captopril 35 Unlicensed: extemporaneous (modification to licensed drug)
Furosemide 18 Unlicensed: extemporaneous (modification to licensed drug)
Diclofenac sodium 6 Unlicensed: product produced under ‘specials’ license
Beclomethasone 4 Unlicensed: imported drug licensed for use in another country
Hydroxytryptophan 2 Unlicensed: imported drug licensed for use in another country













Neonatal 2.47 (1.29–3.82) 0.0001 1.80 (1.03–3.59) 0.009
Surgical 0.71 (0.39–1.49) 0.442 0.81 (0.46–2.10) 0.564
No. of medications
1-3 Ref Ref
4-6 1.19 (0.60–1.89) 0.21 1.06 (0.52–1.44) 0.601
C 7 1.48 (0.57–1.98) 0.04 0.81 (0.36–1.29) 0.649
Age (year)
0-1 2.99 (1.23–4.10) 0.005 1.99 (0.88–3.73) 0.021
2-5 1.92 (1.01–2.99) 0.01 1.15 (0.51–1.71) 0.113
6-10 1.11 (0.58–1.35) 0.13 1.01 (0.59–1.60) 0.501
C 11 Ref Ref
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administered at a dosage higher than that recorded in the
product license (e.g. 75 vs. 50 mg kg-1 day-1 for ceftri-
axone and 150 versus a maximum of 100 mg kg-1 day-1
for cefuroxime in children with severe pneumonia) [31].
Among the medicines licensed for paediatric use, but used
off-label due to dose or indication were ipratropium,
budesonide, salbutamol and adrenaline in various combi-
nations and dosages.
The observed number of cases of unlicensed use
(n = 65), highlights the difficulty in accessing medicines
which are licensed for use in common diseases in children
necessitating the need for the extemporaneous preparation
of medicines. Such preparations often lack bioavailability
data and there is an increased risk of poor therapeutic
outcomes due to dosage errors, especially when younger
children are involved [32]. Moreover, there can also be a
problem of limited availability of these extemporaneous
preparations in the outpatient setting after the child is
discharged from hospital [33]. Drugs that were prescribed
in an off-label or unlicensed manner included meropenem
(contraindicated in children less than 3 months), etanercept
for rheumatoid arthritis in two cases (safety not established
to use in children less than 8 years) and hydroxytryptophan
which was prescribed in two cases for phenylketonurea
with impaired dopamine production. Other examples were
aminophylline which was used for apnea and asprin for
Kawasaki disease.
The study shows that children from birth to 1 year were
more likely to receive off-label medications in multivariate
analysis, as demonstrated by others studying a general
paediatric population [20]. In another study conducted in
Finland, 51% of the children with an off-label prescription
and 72% of those with prescriptions for unlicensed drugs
were below 2 years of age [12]. Such findings usually
reflect the lack of information on appropriate use of med-
ication for younger children [12]. Because neonates and
infants are known to have important differences in drug
absorption, distribution, metabolism, and elimination
compared with older children, the use of medications with
limited safety and efficacy data in this population is par-
ticularly concerning and warrants further study.
Off-label and unlicensed use of medicines in children
should not be ignored or simply accepted as part of normal
paediatric practice. Turner et al. [6] and Santos et al. [13]
have shown that adverse drug reactions are a significant
problem following such use. The lack of clinical trials in
children is often used to justify the unlicensed use of
medicines in this group [34, 35]. However, more efforts are
needed to overcome this problem by encouraging phar-
maceutical companies and researchers to evaluate more
drugs to obtain adequate information on their safety and
efficacy in paediatric patients [36, 37].
In parallel to the European Paediatric Initiative [38], The
Ministry of Health in the Palestinian Authority are striving
to put in place measures to improve the situation for pae-
diatric patients. During the licensing process of each
medicine in Palestine, labelled information regarding pae-
diatric use is checked and complementary information
requested from the manufacturer if deemed necessary. If
such information is not available, the licensing status of the
medicine for use in children in the country of origin is
checked and this information, together with expert opinion,
is used to decide licensing status in Palestine.
This study was limited to inpatient resource-utilisation
data in two clinical centres and as such data are not gen-
eralisable across Palestine nor does it provide data on
outpatient use of off-label and unlicensed medications.
Many medications such as anticancer, antiepileptic, and
immunosuppressive agents are frequently used by children
in the outpatient setting in Palestine and require further
research. Moreover, the sample in the surgical ward was
relatively small.
Conclusion
The present study suggests a high prevalence of unlicensed
and off-label drug use in children in Palestine. For ethical
reasons, standards of drug efficacy and safety should apply
equally in adults and in children and as such the present
and previous studies of drug use in children support the
need to perform more well designed and conducted studies,
particularly in newborns.
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